News headlines about Cleveland BioLabs (NASDAQ:CBLI) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.2209320781715 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Cleveland BioLabs (NASDAQ:CBLI) traded up $0.15 during trading hours on Friday, reaching $2.66. The company’s stock had a trading volume of 41,755 shares, compared to its average volume of 24,767. Cleveland BioLabs has a twelve month low of $1.22 and a twelve month high of $5.55.

Cleveland BioLabs (NASDAQ:CBLI) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.11) EPS for the quarter. The business had revenue of $0.30 million for the quarter. Cleveland BioLabs had a negative net margin of 472.44% and a negative return on equity of 91.87%.

Separately, ValuEngine cut Cleveland BioLabs from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

TRADEMARK VIOLATION WARNING: “Cleveland BioLabs (CBLI) Receiving Somewhat Positive Media Coverage, Analysis Shows” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/cleveland-biolabs-cbli-receiving-somewhat-positive-media-coverage-analysis-shows/1756240.html.

About Cleveland BioLabs

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

Insider Buying and Selling by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.